Guide · Updated April 2026

Survodutide: The GLP-1/Glucagon Agonist for Fatty Liver

Survodutide is a dual GLP-1 and glucagon receptor agonist developed by Boehringer Ingelheim for metabolic dysfunction-associated steatohepatitis (MASH) and obesity. In Phase 2 trials, 83% of patients on survodutide saw MASH improvement versus 18% on placebo, with up to 14.9% body weight loss at 46 weeks. The FDA granted Breakthrough Therapy Designation in September 2024, and Phase 3 results are expected in the first half of 2026.

About 30% of U.S. adults have fatty liver disease. Most do not know it. Survodutide, a dual GLP-1/glucagon receptor agonist, is one of the first drugs designed to treat the root metabolic causes of this condition rather than just managing symptoms. Its Phase 2 results, published in the New England Journal of Medicine in June 2024, showed the kind of liver improvements that no existing drug had delivered before.

I have been tracking the GLP-1 space closely since starting Mounjaro for body composition reasons and monitoring my results with DEXA scans. Survodutide is not available yet, but the data behind it is worth understanding, especially if you care about metabolic health beyond the number on the scale.

What Is Survodutide and How Does It Work?

Survodutide (formerly BI 456906) activates two receptors: the GLP-1 receptor and the glucagon receptor. Most GLP-1 drugs you know, like semaglutide and tirzepatide, work primarily through GLP-1 receptor activation. Tirzepatide adds GIP receptor activation on top of that. Survodutide takes a different path by pairing GLP-1 with glucagon.

Why glucagon? It sounds counterintuitive. Glucagon raises blood sugar, which is the opposite of what you want in a diabetes drug. But glucagon also does something else: it increases energy expenditure in the liver and promotes fat oxidation. In other words, it tells your liver to burn stored fat.

The combination works like this:

• GLP-1 activation reduces appetite, slows gastric emptying, and improves insulin sensitivity (the same mechanism behind Ozempic and Wegovy)
• Glucagon activation increases hepatic fat oxidation, boosts energy expenditure, and reduces liver fat content
• Together, they target both the metabolic drivers of fatty liver and the caloric surplus that feeds it

This dual mechanism is what makes survodutide particularly interesting for MASH, a condition where excess liver fat triggers inflammation and scarring (fibrosis). No other approved GLP-1 medication was specifically designed to address liver fat through glucagon signaling.

Survodutide Phase 2 MASH Trial Results

The Phase 2 MASH trial results were published in the New England Journal of Medicine (NEJMoa2401755) in June 2024. This was a 48-week, randomized, double-blind, placebo-controlled study in adults with biopsy-confirmed MASH and liver fibrosis stages F1 through F3.

The headline numbers:

These are striking numbers. For context, the only FDA-approved MASH drug as of early 2026, resmetirom (Rezdiffra), showed MASH resolution in about 26-30% of patients. Survodutide nearly doubled that in Phase 2.

The trial also showed significant reductions in liver enzymes (ALT and AST), which are markers of liver inflammation. Patients on survodutide saw their liver enzyme levels drop toward normal ranges during treatment.

What About Fibrosis Specifically?

Fibrosis improvement was more modest: 36% on survodutide versus 22% on placebo at the 4.8 mg dose. Fibrosis takes longer to reverse than fat accumulation, so the 48-week window may not have been long enough to see the full effect. The Phase 3 LIVERAGE trial runs for 52 weeks on the primary endpoint, with long-term follow-up extending to approximately seven years to measure whether survodutide reduces the risk of end-stage liver disease.

Survodutide Weight Loss Data

Survodutide was also tested separately for obesity in a Phase 2 dose-finding trial published in The Lancet Diabetes & Endocrinology in February 2024. This was a 46-week study in adults with overweight or obesity but without diabetes.

The weight loss results by dose:

At the highest dose (4.8 mg), 83% of participants lost at least 5% of their body weight, 69% lost at least 10%, and 55% lost at least 15%. Notably, weight loss had not plateaued at 46 weeks, suggesting longer treatment could produce even greater results.

Participants also saw reductions in waist circumference (up to 16.0 cm) and blood pressure (systolic down up to 8.6 mmHg, diastolic down up to 4.8 mmHg).

How Does This Compare to Other GLP-1s?

Survodutide’s weight loss at 46 weeks roughly matches what Wegovy achieved at 68 weeks in STEP 1 (NEJM, 10.1056/NEJMoa2032183). That is a faster trajectory. But it falls short of tirzepatide at the highest dose in SURMOUNT-1 (NEJM, 10.1056/NEJMoa2206038), which hit 22.5% at 72 weeks.

The real differentiator for survodutide is not raw weight loss. It is the liver-specific benefits that come from glucagon receptor activation. If you only care about losing weight, tirzepatide remains the strongest option currently available. If you have fatty liver disease or elevated liver enzymes, survodutide targets your specific problem in a way that existing GLP-1s do not.

Side Effects: The Honest Picture

Survodutide’s side effect profile is heavier on GI symptoms than most approved GLP-1 medications. This is the part of the story that does not get enough attention.

In the Phase 2 MASH trial, the GI side effect rates were:

For comparison, nausea rates in SURMOUNT-1 for tirzepatide ranged from 24-31%, and in STEP 1 for semaglutide about 44%. Survodutide’s 66% nausea rate is notably higher.

About 20% of survodutide-treated patients discontinued treatment due to adverse events in the MASH trial, compared to 3% on placebo. Most dropouts happened during the dose escalation phase in the first six weeks.

There is a reason for this. The Phase 2 trials used a rapid 20-week dose escalation schedule. Boehringer Ingelheim has adjusted the Phase 3 design with slower titration and the option to pause dosing temporarily if GI symptoms become severe. This mirrors what happened with semaglutide and tirzepatide, where managing nausea through slower titration became standard practice.

Serious adverse events occurred at similar rates between survodutide (8%) and placebo (7%), which is reassuring. The GI issues are unpleasant but not dangerous in the vast majority of cases.

If you have experience with GLP-1 side effects, you know the pattern: GI symptoms are worst during dose increases and typically settle over time. The same appears to be true for survodutide.

Phase 3 Trials: What to Watch For

Survodutide has two major Phase 3 programs running:

For obesity (SYNCHRONIZE program):

• SYNCHRONIZE-1 and SYNCHRONIZE-2: Testing survodutide for weight management in adults with and without type 2 diabetes. Results expected H1 2026.
• SYNCHRONIZE-CVOT: A cardiovascular outcomes trial, similar to SELECT for semaglutide. This will take years to complete.

For MASH (LIVERAGE program):

• LIVERAGE: Testing whether survodutide improves MASH and fibrosis at 52 weeks, with long-term follow-up of approximately seven years for end-stage liver disease outcomes. Enrollment in adults with moderate to advanced fibrosis (F2-F3).
• LIVERAGE-Cirrhosis: Testing survodutide in adults with MASH and compensated cirrhosis (F4), with approximately four and a half years of follow-up.

The FDA has granted both Fast Track Designation and Breakthrough Therapy Designation for survodutide in MASH. The European Medicines Agency granted access to its PRIME scheme, which is the EU equivalent. These designations speed up the regulatory review process but do not guarantee approval.

If Phase 3 results match Phase 2, survodutide could reach the market for MASH by 2027-2028. Obesity approval would follow a separate timeline.

Survodutide vs. the Next-Gen GLP-1 Pipeline

Survodutide is not the only dual or multi-agonist in development. Here is how it fits into the broader pipeline:

Retatrutide is the most direct competitor because it also activates the glucagon receptor (plus GIP). It produced stronger weight loss in Phase 2 but has not yet published MASH-specific data at the level survodutide has. The MASH data is survodutide’s biggest advantage right now.

Pemvidutide is another GLP-1/glucagon dual agonist from Altimmune, but its Phase 2b results published in The Lancet showed more modest weight loss and MASH improvements compared to survodutide.

Who Might Benefit Most from Survodutide?

Based on the trial data, survodutide looks most promising for:

1. People with MASH or NAFLD who need targeted liver fat reduction beyond what current GLP-1 medications provide
2. People with elevated liver enzymes (ALT/AST) alongside obesity, where liver-specific treatment matters
3. People who respond well to GLP-1 therapy but need additional metabolic benefits for liver health

If you do not have fatty liver disease and your primary goal is weight loss, the currently available options (Mounjaro, Zepbound, or Wegovy) are likely more relevant. You can compare them in our medication comparison guide or check the cheapest ways to access GLP-1 medications right now.

For those tracking body composition closely, the combination of weight loss and liver fat reduction is interesting. DEXA scans track overall lean vs. fat mass, but they do not measure organ-specific fat. An abdominal ultrasound or FibroScan is what you need to monitor liver fat specifically.

The Bottom Line

Survodutide’s Phase 2 data for MASH is the best we have seen from any GLP-1 class medication. An 83% improvement rate in fatty liver disease, combined with meaningful weight loss and a mechanism specifically designed to target liver fat, puts it in a class of its own for now. The GI side effects are rougher than existing options, but Boehringer Ingelheim is adjusting dose escalation for Phase 3 to address that.

This drug is not available yet. Phase 3 results should arrive in 2026, with a potential FDA approval for MASH in 2027-2028. If you have fatty liver disease today, talk to your doctor about current options. If you are already on a GLP-1 and want to monitor your metabolic health, tracking your body composition with our body composition calculator is a good starting point.

FAQ

This article is for informational purposes only and does not constitute medical advice. Always consult with a qualified healthcare provider before starting any medication. ClearMetabolic may earn a commission through provider links on this page. See our full disclosure.

Related

Guides:

• Cheapest GLP-1 Online · Side Effects Guide · Body Composition Guide
• Amycretin vs Tirzepatide · DEXA Scan Results · Insurance Coverage

Provider Reviews: Ro · Hims · MEDVi

Compare: All Providers · Best GLP-1 Programs · All Guides